BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25499799)

  • 1. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
    Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
    Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
    Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
    J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
    Youdim MB; Kupershmidt L; Amit T; Weinreb O
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
    Zhao Q; Cai D; Bai Y
    Int J Mol Med; 2013 Oct; 32(4):883-91. PubMed ID: 23877198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Bar-Am O; Youdim MB
    Neuroscience; 2011 Aug; 189():345-58. PubMed ID: 21570450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M; Sanz E
    Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
    Gal S; Abassi ZA; Youdim MB
    Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice.
    Golko-Perez S; Amit T; Youdim MB; Weinreb O
    J Mol Neurosci; 2016 Aug; 59(4):504-10. PubMed ID: 27173029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe
    Aguirre P; García-Beltrán O; Tapia V; Muñoz Y; Cassels BK; Núñez MT
    ACS Chem Neurosci; 2017 Jan; 8(1):178-185. PubMed ID: 27806193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.